In a report released today, Brooks O’Neil from Lake Street maintained a Buy rating on Harrow Health, with a price target of $70.00. The company’s shares closed last Friday at $45.43.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, O’Neil is ranked #6297 out of 10027 analysts.
Harrow Health has an analyst consensus of Strong Buy, with a price target consensus of $64.86, which is a 42.77% upside from current levels. In a report released on October 1, B. Riley Securities also maintained a Buy rating on the stock with a $74.00 price target.
Based on Harrow Health’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $63.74 million and a net profit of $5 million. In comparison, last year the company earned a revenue of $48.94 million and had a GAAP net loss of $6.47 million
Read More on HROW:
/Semiconductor%20by%20Gorodenkoff%20via%20Shutterstock.jpg)
/An%20image%20of%20a%20Tesla%20humanoid%20robot%20in%20front%20of%20the%20company%20logo%20Around%20the%20World%20Photos%20via%20Shutterstock.jpg)
